Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry.
Pharmacogenomics. 2010 Sep;11(9):1305-30
Authors: Shiroma PR, Geda YE, Mrazek DA
Response to psychiatric medications in later life is highly heterogeneous and complex. Monoaminergic-related polymorphisms may influence medication response and susceptibility to side effects in elderly individuals.
Pharmacogenomic strategies against microbial resistance: from bright to bleak to innovative.
Pharmacogenomics. 2010 Sep;11(9):1193-6
Authors: Dandekar T, Dandekar G
The last decade saw an alarming increase in antibiotic resistance in infections, with more than 13 million deaths per year from infections. Counter strategies include hygiene, antibiotic restriction and new antibiotics such as quinupristin, linezolid, tigecycline, daptomycin and dalbavancin.
First results of largest study of genomes and cancer treatments available.
Pharmacogenomics. 2010 Sep;11(9):1197-8
Authors:
PMID: 20860458 [PubMed - indexed for MEDLINE]
Influence of mtDNA genetic variation on antibiotic therapy.
Pharmacogenomics. 2010 Sep;11(9):1185-7
Authors: Pacheu-Grau D, Gómez-Durán A, Montoya J, Ruiz-Pesini E
PMID: 20860455 [PubMed - indexed for MEDLINE]
Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
Pharmacogenomics. 2010 Sep;11(9):1269-85
Authors: Loo TT, Ross CJ, Sistonen J, Visscher H, Madadi P, Koren G, Hayden MR, Carleton BC
Juxtaposing clinical pharmacology with human genetics, pharmacogenomics utilizes a patient's genetic information to identify genetic variants that have the potential to provide clinically relevant predictions of toxicity and efficacy.
A recently concluded cooperative R&D project at the FDA led to the development of a web-enabled software tool that will be useful for modeling the impact of predictive biomarkers on the complexity and cost of clinical development programs. Hear from the project's FDA Principal Investigator and from Adaptive Pharmacogenomic's PI on the project in a pair of webinars, August 24 and 25.
Pharmacogenetics of osteoporosis-related bone fractures: moving towards the harmonization and validation of polymorphism diagnostic tools.
Pharmacogenomics. 2010 Sep;11(9):1287-303
Authors: Rojo Venegas K, Aguilera Gómez M, Eisman JA, García Sánchez A, Faus Dader MJ, Calleja Hernández MA
Osteoporosis is one of the most common skeletal chronic conditions in developed countries, hip fracture being one of its major healthcare outcomes.
Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine.
Pharmacogenomics.